Piper Sandler Resumes Supernus Pharmaceuticals at Overweight
Bullish analyst initiation, with substantial stated target upside; treat as opinion-based rather than a confirmed catalyst.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Bullish analyst initiation, with substantial stated target upside; treat as opinion-based rather than a confirmed catalyst.
What happened, with direct paths to the underlying reporting
Piper Sandler resumed coverage of SUPN with an Overweight rating and a $47 target, about 67% above the posted price of $28.15. The target is an analyst opinion, not a forecast guarantee.
Target: $47
Posted price: $28.15
Analyst firm: Piper Sandler
Analyst: David Amsellem
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.